Arch Therapeutics (ARTH)
(Delayed Data from OTC)
$0.77 USD
0.00 (0.00%)
Updated Jul 23, 2024 01:25 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Arch Therapeutics, Inc. [ARTH]
Reports for Purchase
Showing records 101 - 115 ( 115 total )
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
Arch Therapeutics Reports Q2: Next Events- AC5''s Reg Filings
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
Arch Therapeutics Presents Favorable Adhesion Severity Data
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
Accelerated Timeline for AC5 510(k) Filing; Raising Price Target
Provider: Rodman & Renshaw, Co.
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
Accelerated Timeline for AC5 510(k) Filing; Raising Price Target
Provider: H.C. Wainwright & Co., Inc.
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
We are initiating coverage with a Buy rating and 12-month price target of $2.50 per share.
Provider: Rodman & Renshaw, Co.
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
ARTH Initiation: AC5 to Revolutionize the Hemostat Market; Buy Rated, $3.00 PT
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
Stopping Bleeding Using Self-Assembling Peptides; Initiating at Buy and $2.50 Target
Provider: H.C. Wainwright & Co., Inc.
Company: Arch Therapeutics, Inc.
Industry: Unclassified
We initiate coverage with a price target of $1.50 per share.
Provider: SEETHRUEQUITY, LLC
Analyst: TANDON A